Reportlinker Adds Pharmaceuticals Reports Bundle

Monday, May 16, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 16, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:


Reports Bundle

Report Description

The Pharmaceuticals Reports Bundle

includes the following TriMark Publications reports at a 15% discount off the individual reports being purchased separately:

- Anti-Infective Drugs Markets.

- Cell Therapy Markets.

- Cell-Based Assays for Drug Discovery.

- Companion Biomarkers in Drug Development.

- Indian Pharmaceutical Industry.

- Medical Nanotechnology Markets.

- Pharmacogenomics for Clinical Use and in Drug Development.

- Therapeutic Monoclonal Antibodies Markets.

Below are summaries of each report.

- Anti-Infective Drugs Markets

Six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults, according to the World Health Organization (WHO). Moreover, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world. This report analyzes the anti-infective drugs market and highlights the existing and developing anti-infectives used to ameliorate infectious diseases' afflictions on humankind. Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective drugs with specific emphasis on each company's sales focus, product portfolio and R&D pipeline. To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing anti-infective drugs markets, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively. Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA. What's more, this study will examine the existing and developing anti-infective drugs targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid and yellow fever.

- Cell Therapy Markets

Cell therapy technologies and methods have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Cell therapy is bound to become a part of medical practice. Unlike organs, cells are a potentially renewable resource for body repair. The goal of this TriMark Publications report is to review the market for cell therapy products using screening reagents and instruments for analysis of individual components in tissue samples, blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of cell therapy and the factors that influence purchases are discussed. The study surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the cell therapy market in the U.S. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

- Cell-Based Assays for Drug Discovery

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types--primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment.

- Companion Biomarkers in Drug Development

The term "companion biomarker" means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease. Biomarkers can be used in five very distinct ways in drug development: 1) companion biomarkers can be correlated with biological events during drug development in order to validate drug targets or to predict drug response; 2) biomarkers can be used as companion diagnostics in drug development to characterize patient populations in order to better understand the extent to which new drugs reach intended therapeutic targets can alter proposed therapeutic pathways and achieve successful clinical outcomes; 3) biomarkers can be used to stratify patient populations for drug response in primary prevention or disease-modification studies, particularly in specific clinical areas such as neuron degeneration and cancer; 4) clinically useful biomarkers are becoming increasingly useful to make proper therapeutic decisions regarding candidate drugs; and 5) clinically useful biomarkers are becoming increasingly required by the FDA and other outside authorities to make proper regulatory decisions regarding candidate drugs. This TriMark Publications report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.

- Indian Pharmaceutical Industry

The purpose of this TriMark Publications study is to describe the specific segment of the pharmaceutical market sector called the Indian pharmaceutical industry. This sector includes all of the generally-accepted pharmaceutical manufacturing activities that are currently used today, including the bulk drug industry, formulations and major therapeutic segments. It examines these clinical supplies as utilized in hospitals, clinics and doctor's offices. The principal objectives of this analysis are to: 1) identify viable technology drivers through a comprehensive look at various platform technologies for the Indian pharmaceutical industry; 2) obtain a complete understanding of the Indian pharmaceutical industry practices from its basic principles to its applications; 3) discover feasible market opportunities via an identification of high-growth applications in different areas of the Indian pharmaceutical industry, with a focus on the biggest and expanding markets for the Indian pharmaceutical industry; 4) focus on global industry development through an in-depth analysis of the major world markets for pharmaceutical manufacturing, including forecasts for growth; and 5) establish the essentials of the Indian pharmaceutical market including definitions, processes and trends

- Medical Nanotechnology Markets

Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare. This TriMark Publications report covers the specific segments of the medical nanotechnology markets, with particular emphasis on those segments where this emerging technology is or shows the potential to be most impactful. Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery and medical technologies. The discipline has already yielded healthcare discoveries that have been used for drug delivery and diagnostic purposes. In this study, we describe various nanotechnologies under development for biological and medical purposes and assess their potential. Moreover, this analysis is arranged to provide an overview of the regulatory issues faced by the medical nanotechnology industry and focuses on how specific segments within the industry are poised for high future growth.

- Pharmacogenomics for Clinical Use and in Drug Development

growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some, but not all, of the patients to whom they were administered. Additionally, reducing the occurrence of adverse effects to a drug effectually reduces the cost of patient care overall. This TriMark Publications study examines the market for diagnostic tests based on this science and the clinical measurement methods, the reagents and supplies being utilized in clinical medicine and the pharmaceutical industry. This report presents an overview of the latest information regarding emerging new products and industry trends and will not only quantify, but also, qualify the pharmacogenomic market segments as an area of research, product development and investment opportunity. Forecasts of the pharmacogenomic market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and the immense possibilities of the future.

- Therapeutic Monoclonal Antibodies Markets

Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system through recombinant DNA technology that has the ability to combine specifically with a target protein that plays a role in a disease process. With this unique ability to specifically target diseased cells while leaving healthy cells unaffected, monoclonal antibodies can serve to diagnose and treat a wide range of medical conditions. Areas such as breast cancer therapy have benefited greatly since the advent of drugs like Herceptin (trastuzumab) that interferes with the HER2/neu receptor. Indeed, the field of therapeutic monoclonal antibodies potentially has far-reaching and paradigm-shifting implications for biology, drug discovery, and medical treatment of disease. The discipline has already yielded discoveries that have been used for drug delivery and diagnostic purposes, and other exciting new therapeutic applications. This TriMark Publications report reviews the market for medical products based on emerging therapeutic monoclonal antibodies. It defines the dollar volume of sales in the U.S. and worldwide, and it analyzes the factors that influence the size and the growth of the market segments. The study goes on to discuss in detail the trends that have developed which have stimulated this market and surveys many of the companies marketing, manufacturing or developing monoclonal antibodies therapies. Monoclonal antibodies for non-therapeutic purposes--used primarily in life science and research applications--are not discussed in this review. Moreover, antibody process technology is not covered. Special effort was made to include mention of smaller companies that are or potentially could have an impact on their industry far in excess of their current size. Each company is discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market.

To order this report:

Nanotechnology Industry: Pharmaceuticals Reports Bundle

Nanotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store